Bioactive natural products from marine sponges belonging to family Hymedesmiidae

Natural products of marine origin exhibit extensive biological activities, and display a vital role in the exploration of new compounds for drug development. Marine sponges have been reported at the top with respect to the discovery of biologically active metabolites that have potential pharmaceutic...

Full description

Saved in:
Bibliographic Details
Published in:RSC advances Vol. 11; no. 27; pp. 16179 - 16191
Main Authors: Elgoud Said, Asmaa Abo, Mahmoud, Basma Khalaf, Attia, Eman Zekry, Abdelmohsen, Usama Ramadan, Fouad, Mostafa Ahmed
Format: Journal Article
Language:English
Published: England Royal Society of Chemistry 30.04.2021
The Royal Society of Chemistry
Subjects:
ISSN:2046-2069, 2046-2069
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Natural products of marine origin exhibit extensive biological activities, and display a vital role in the exploration of new compounds for drug development. Marine sponges have been reported at the top with respect to the discovery of biologically active metabolites that have potential pharmaceutical applications. The family Hymedesmiidae belonging to the Demospongiae class includes ten accepted genera, of which four genera were explored for their bioactive metabolites, namely Phorbas , Hamigera , Hemimycale , and Kirkpatrickia . Genus Phorbas has received more attention due to the isolation of various classes of compounds with unique structures mainly diterpenes, alkaloids, sesterterpenes, and steroids that exhibited diverse biological activities including: antiviral, antimicrobial, and anti-inflammatory, whereas anticancer compounds predominated. This review focuses on the isolated secondary metabolites from family Hymedesmiidae with their biological potential and covers the literature from 1989 to 2020. Natural products of marine origin exhibit extensive biological activities, and display a vital role in the exploration of new compounds for drug development.
Bibliography:10.1039/d1ra00228g
Electronic supplementary information (ESI) available. See DOI
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Review-3
ISSN:2046-2069
2046-2069
DOI:10.1039/d1ra00228g